Rastogi Anjay, Nissenson Allen R
UCLA Medical Center, Los Angeles, CA 90095, USA.
Adv Chronic Kidney Dis. 2007 Jul;14(3):249-55. doi: 10.1053/j.ackd.2007.05.001.
The worldwide epidemic of chronic kidney disease shows no signs of abating in the near future. Current dialytic forms of renal replacement therapy (RRT), even though successful in sustaining life and improving quality of life somewhat for patients with end-stage renal disease, have many limitations that result in still unacceptably high morbidity and mortality. Transplantation is an excellent option but is limited by the scarcity of organs. An ideal form of RRT would mimic the functions of natural kidneys and be implantable, safe, and cost-effective. Until recently, these goals would have been hard to achieve, but with the application of nanotechnology and microfluidics to RRT, they appear closer than ever before. Newer approaches include the human nephron filter (HNF), a novel form of RRT consisting of 2 membranes in series. The first membrane mimics the function of the glomerulus, and the other membrane mimics the function of the tubule. Investigators have proposed the synthesis of a silicone membrane that more closely resembles the glomerular filtration membrane and the use of a membrane with implanted renal tubular cells to provide tubular and other kidney functions. Membraneless dialysis that utilizes the principle of microfluidics has been proposed. Application of microelectromechanical systems (MEMS) technology will provide the ideal miniature detection system for future implantable dialysis devices. Finally, stem cells hold much promise, both for kidney disease and as a source of tissues and organs. In summary, nephrology is at an exciting crossroad with the application of innovative and novel technologies to RRT that hold considerable promise for the near future.
全球慢性肾脏病的流行在近期没有减弱的迹象。目前的肾脏替代治疗(RRT)透析形式,尽管在维持终末期肾病患者的生命并在一定程度上改善其生活质量方面取得了成功,但仍有许多局限性,导致发病率和死亡率居高不下,令人难以接受。肾移植是一个很好的选择,但受到器官稀缺的限制。理想的RRT形式应能模拟天然肾脏的功能,并且可植入、安全且具有成本效益。直到最近,这些目标还很难实现,但随着纳米技术和微流控技术应用于RRT,它们似乎比以往任何时候都更接近现实。新的方法包括人类肾单位过滤器(HNF),这是一种新型的RRT形式,由两个串联的膜组成。第一个膜模拟肾小球的功能,另一个膜模拟肾小管的功能。研究人员提出合成一种更类似于肾小球滤过膜的硅膜,并使用植入肾小管细胞的膜来提供肾小管及其他肾脏功能。有人提出了利用微流控原理的无膜透析。微机电系统(MEMS)技术的应用将为未来的可植入透析设备提供理想的微型检测系统。最后,干细胞在治疗肾病以及作为组织和器官的来源方面都有很大的前景。总之,随着创新和新技术应用于RRT,肾脏病学正处于一个令人兴奋的十字路口,在不久的将来有着相当大的前景。